Genentech Posts Higher Earnings

BMC Software lowers outlook; SpectraLink sees lower revenue; plus more of Tuesday's stocks in the news

Genentech (DNA ) posted 29 cents, vs. 19 cents first-quarter earnings per share on 50% higher operating revenue and 55% higher total product sales. The company posts Avastin U.S. sales of $675.9 million, which is below some Street estimates. It expects 2005 earnings per share growth of greater than 30%.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.